DIATHEVA - Biomanufacturing of innovative diagnostics and reagents

Magazine / Items filtered by date: January 2016

DIATHEVA - Biomanufacturing of innovative diagnostics and reagents - Items filtered by date: January 2016

EMA acts upon request from European Commission following detection of colistin-resistant bacteria

EMA acts upon request from European Commission following detection of colistin-resistant bacteria

The European Medicines Agency (EMA) has received a request from the European Commission to update its advice on the use in animals of colistin, which is one of the last-resort antibiotics to treat certain bacterial infections in humans. Read more

New pubblication Diatheva's pipeline antibody therapeutics

Diatheva’s pipeline antibody-based therapies is designated to address significant unmet medical needs and by its productive technology suite capable of selecting, manufacturing in GMP compliance and characterizing innovative next generation recombinant antibody therapeutics.
Published article: Process development of a human recombinant diabody expressed in E.coli: engagment of CD99 induced apoptosis for target therapy in Ewing’s sarcoma

 

Company certified
ISO9001
Certified N.
IT05/0576
crm@diatheva.com
Phone (+39) 0721 830605
Fax (+39) 0721 837154
 
website netcompany
P.IVA.01403060427

By navigating this website you provide your agreement to the use of cookies, which we use to improve your navigation experience and for statistical analysis. Read our Cookie Policy to learn more

Your Shopping Cart

 x 
Cart empty